Theravance Biopharma, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Theravance Biopharma, Inc. (TBPH) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $2.10M, a 318.29% increase year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $5.82M, a 565.68% increase year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-12-31 was $1.98M, a 274.81% increase year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $678.00K, a 70.78% increase year-over-year.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $4.03M, a 51.71% increase from fiscal 2024.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $2.66M, a 6.36% increase from fiscal 2023.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $2.50M, a 27.54% decline from fiscal 2022.
- Theravance Biopharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $3.45M, a 61.92% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.10M 10-Q · filed 2026-08-11 | $7.92M 10-Q · filed 2026-08-11 | $9.90M derived: sum of 3 quarters · filed 2026-08-11 | $10.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $5.82M 10-Q · filed 2026-05-07 | $7.80M derived: sum of 2 quarters · filed 2026-05-07 | $8.47M derived: sum of 3 quarters · filed 2026-05-07 | $8.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.66M derived: sum of 2 quarters · filed 2026-03-23 | $3.16M derived: sum of 3 quarters · filed 2026-08-11 | $4.03M 10-K · filed 2026-03-23 |
| 2025-09-30 | $678.00K 10-Q · filed 2025-11-12 | $1.18M derived: sum of 2 quarters · filed 2026-08-11 | $2.06M 10-Q · filed 2025-11-12 | $2.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $503.00K 10-Q · filed 2026-08-11 | $1.38M 10-Q · filed 2026-08-11 | $1.91M derived: sum of 3 quarters · filed 2026-08-11 | $2.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $874.00K 10-Q · filed 2026-05-07 | $1.40M derived: sum of 2 quarters · filed 2026-05-07 | $1.80M derived: sum of 3 quarters · filed 2026-05-07 | $2.26M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $925.00K derived: sum of 2 quarters · filed 2026-03-23 | $1.39M derived: sum of 3 quarters · filed 2026-03-23 | $2.66M 10-K · filed 2026-03-23 |
| 2024-09-30 | $397.00K 10-Q · filed 2025-11-12 | $861.00K derived: sum of 2 quarters · filed 2025-11-12 | $2.13M 10-Q · filed 2025-11-12 | $2.65M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $464.00K 10-Q · filed 2025-08-13 | $1.73M 10-Q · filed 2025-08-13 | $2.25M derived: sum of 3 quarters · filed 2025-08-13 | $2.77M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-12 | $1.79M derived: sum of 2 quarters · filed 2025-05-12 | $2.30M derived: sum of 3 quarters · filed 2025-05-12 | $2.88M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $518.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.03M derived: sum of 2 quarters · filed 2025-03-07 | $1.61M derived: sum of 3 quarters · filed 2025-03-07 | $2.50M 10-K · filed 2025-03-07 |
| 2023-09-30 | $512.00K 10-Q · filed 2024-11-14 | $1.09M derived: sum of 2 quarters · filed 2024-11-14 | $1.98M 10-Q · filed 2024-11-14 | $2.98M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $583.00K 10-Q · filed 2024-08-08 | $1.47M 10-Q · filed 2024-08-08 | $2.46M derived: sum of 3 quarters · filed 2024-08-08 | $3.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $887.00K 10-Q · filed 2024-05-15 | $1.88M derived: sum of 2 quarters · filed 2024-05-15 | $2.54M derived: sum of 3 quarters · filed 2024-05-15 | $2.89M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.66M derived: sum of 2 quarters · filed 2024-03-01 | $2.00M derived: sum of 3 quarters · filed 2024-03-01 | $3.45M 10-K · filed 2024-03-01 |
| 2022-09-30 | $662.00K 10-Q · filed 2023-11-09 | $1.01M derived: sum of 2 quarters · filed 2023-11-09 | $2.46M 10-Q · filed 2023-11-09 | $2.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $347.00K 10-Q · filed 2023-08-09 | $1.79M 10-Q · filed 2023-08-09 | $2.25M derived: sum of 3 quarters · filed 2023-08-09 | $4.54M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.45M 10-Q · filed 2023-05-10 | $1.90M derived: sum of 2 quarters · filed 2023-05-10 | $4.19M derived: sum of 3 quarters · filed 2023-05-10 | $4.92M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.74M derived: sum of 2 quarters · filed 2023-03-01 | $3.47M derived: sum of 3 quarters · filed 2023-03-01 | $9.06M 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.29M 10-Q · filed 2022-11-09 | $3.01M derived: sum of 2 quarters · filed 2022-11-09 | $8.61M 10-Q · filed 2022-11-09 | $9.42M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $727.00K 10-Q · filed 2022-08-08 | $6.32M 10-Q · filed 2022-08-08 | $7.13M derived: sum of 3 quarters · filed 2023-03-01 | $8.12M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $5.59M 10-Q · filed 2022-05-06 | $6.41M derived: sum of 2 quarters · filed 2023-03-01 | $7.39M derived: sum of 3 quarters · filed 2023-03-01 | $8.54M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.80M derived: sum of 2 quarters · filed 2023-03-01 | $2.94M derived: sum of 3 quarters · filed 2023-03-01 | $9.75M 10-K · filed 2023-03-01 |
| 2020-09-30 | $987.00K 10-Q · filed 2021-11-08 | $2.13M derived: sum of 2 quarters · filed 2021-11-08 | $8.94M 10-Q · filed 2021-11-08 | $9.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.14M 10-Q · filed 2021-08-05 | $7.95M 10-Q · filed 2021-08-05 | $8.38M derived: sum of 3 quarters · filed 2022-02-28 | $8.94M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $6.80M 10-Q · filed 2021-05-06 | $7.23M derived: sum of 2 quarters · filed 2022-02-28 | $7.80M derived: sum of 3 quarters · filed 2022-02-28 | $8.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $992.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.49M derived: sum of 3 quarters · filed 2022-02-28 | $3.17M 10-K · filed 2022-02-28 |
| 2019-09-30 | $562.00K 10-Q · filed 2020-11-09 | $1.06M derived: sum of 2 quarters · filed 2020-11-09 | $2.74M 10-Q · filed 2020-11-09 | $4.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $494.00K 10-Q · filed 2020-08-10 | $2.18M 10-Q · filed 2020-08-10 | $3.54M derived: sum of 3 quarters · filed 2021-02-26 | $5.08M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $1.69M 10-Q · filed 2020-05-08 | $3.04M derived: sum of 2 quarters · filed 2021-02-26 | $4.59M derived: sum of 3 quarters · filed 2021-02-26 | $9.78M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.90M derived: sum of 2 quarters · filed 2021-02-26 | $8.09M derived: sum of 3 quarters · filed 2021-02-26 | $9.81M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.55M 10-Q · filed 2019-11-08 | $6.74M derived: sum of 2 quarters · filed 2019-11-08 | $8.45M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $5.19M 10-Q · filed 2019-08-05 | $6.91M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $1.72M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $8.56M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $3.87M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $756.00K 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $178.00K 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |